Table 5 (Part 1). Other HCL cohorts with cancer incidence during follow-up. (Part 2). Other HCL cohorts with cancer incidence during follow-up.

Hisada et al.

Retrospective

6.5 years

32% at 25 years^a

1.24 (1.11; 1.37)

Kampmeier et al.

Prospective

IFNα

91 months

19%^a

4.33

Goodman et al.

Retrospective

Cladribine

≥7 years

23%^a

2.03 (1.49; 2.71)

Saven et al.

Retrospective

Cladribine

58 months

8%^a

1.88 (1.24; 2.74)

Au et al.

Retrospective

Cladribine

pentostatin

splenectomy

IFNα

68 months

24%^a

2.60 (1.82; 3.61)

Paltiel et al.

Retrospective

Cladribine

80 months

11%^b

1.3 (0.68; 2.28) for all cancers

3.23 (1.39; 6.36) for urogenital cancers

Kurzrock et al.

Retrospective

Cladribine

pentostatin

IFNα

6 years

7.40%^b

1.34 for all cancers

13.04 for myelomas

8.7 for lymphomas

Federico et al.

Retrospective

14% at 15 years^b

1.01 (0.74; 1.33) for all cancers

5.3 (1.9; 11.5) for NHL

Else et al.

Retrospective

Pentostatin

cladribine

16 years

12% (excluding nonmelanoma skin cancers)^c

No data

Flinn et al.

Prospective

Pentostatin +/−IFNα

9.3 years

16%^c

1.26 (0.86; 1.77)

Pawson et al.

Retrospective

Cladribine

pentostatin

IFNα

65 months

4%^c

1.29 (0.60; 2.65)

Maloisel et al.

Retrospective

Pentostatin

63.5 months

7.60%^c

0.95 (0.5; 1.92)

Rosenberg et al.

Retrospective

Cladribine

21 years

9.10%^c

1.60 (0.80; 2.89)

Watts et al.

Retrospective

Cladribine

pentostatin

11% at 10 years (melanoma and non-melanoma skin cancers only)^c

1.30 (0.78; 2.03) (for melanoma only)

Troussard et al.

Retrospective

IFNα

102 months

9.5% at 10 years^c

1.24 (0.54; 2.45)

Getta et al.

Retrospective

Cladribine

splenectomy

IFNα

69 months

Age ≤ 40: 21% at 10 years^d

Age > 40: 29% at 10 years^d

No data

Damaj et al.

Retrospective

Cladribine

pentostatin

splenectomy

IFNα

13 years

27+/−6% at 13 years^d

No data